deltatrials
Completed PHASE1 INTERVENTIONAL 3-arm NCT03084640

Phase 1B Study Evaluating Alternative Routes of Administration of CMP-001 in Combination With Pembrolizumab in Participants With Advanced Melanoma

A Multicenter, Two Part, Phase 1B Study Evaluating Alternative Routes of Administration of CMP-001 in Combination With Pembrolizumab in Subjects With Advanced Melanoma

Sponsor: Regeneron Pharmaceuticals

Conditions Malignant Melanoma
Interventions CMP-001 Pembrolizumab
Updated 17 times since 2017 Last updated: Aug 1, 2022 Started: May 4, 2017 Primary completion: Jul 2, 2021 Completion: Sep 30, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Malignant Melanoma, this trial is completed. The trial is conducted by Regeneron Pharmaceuticals and has accumulated 17 data snapshots since 2017. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~May 2017 – ~Jul 2017 · 2 months · monthly snapshot~Jul 2017 – ~Aug 2017 · 31 days · monthly snapshot~Aug 2017 – ~May 2018 · 9 months · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Dec 2018 · 5 months · monthly snapshot~Dec 2018 – ~Dec 2019 · 12 months · monthly snapshot~Dec 2019 – ~Jan 2021 · 13 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Sep 2021 · 7 months · monthly snapshot~Sep 2021 – ~Nov 2021 · 2 months · monthly snapshot~Nov 2021 – ~Jan 2022 · 2 months · monthly snapshot~Jan 2022 – ~Apr 2022 · 3 months · monthly snapshot~Apr 2022 – ~Sep 2022 · 5 months · monthly snapshot~Sep 2022 – ~Jul 2024 · 22 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

17 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Sep 2022 — Jul 2024 [monthly]

    Completed PHASE1

  4. Apr 2022 — Sep 2022 [monthly]

    Completed PHASE1

  5. Jan 2022 — Apr 2022 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

▶ Show 12 earlier versions

  1. Nov 2021 — Jan 2022 [monthly]

    Active Not Recruiting PHASE1

  2. Sep 2021 — Nov 2021 [monthly]

    Active Not Recruiting PHASE1

  3. Feb 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  4. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE1

  5. Dec 2019 — Jan 2021 [monthly]

    Recruiting PHASE1

  6. Dec 2018 — Dec 2019 [monthly]

    Recruiting PHASE1

    Phase: PHASE1_PHASE2 → PHASE1

  7. Jul 2018 — Dec 2018 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Enrolling By Invitation → Recruiting

  8. Jun 2018 — Jul 2018 [monthly]

    Enrolling By Invitation PHASE1_PHASE2

  9. May 2018 — Jun 2018 [monthly]

    Enrolling By Invitation PHASE1_PHASE2

    Status: Recruiting → Enrolling By Invitation

  10. Aug 2017 — May 2018 [monthly]

    Recruiting PHASE1_PHASE2

  11. Jul 2017 — Aug 2017 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet Recruiting → Recruiting

  12. May 2017 — Jul 2017 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Regeneron Pharmaceuticals
Data source: Regeneron Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations